PODD shorts at a year high while options traders turn bullish ahead of earnings

Insulet Corporation makes the Omnipod, a tubeless insulin pump worn on the body and controlled by a smartphone. The company reports Q3 results on November 5, and it enters that moment carrying the most short interest in at least a year while options positioning has swung sharply in the opposite direction, toward calls rather than puts.

Short interest has climbed to 8.2% of the free float, up roughly 10% over the past month and at its highest point in the 30-day history of ORTEX's daily estimate series. The move is gradual rather than a sudden conviction trade: shorts built from about 5.1 million shares in late September to 5.7 million by early November, with most of the acceleration coming after October 23. At three days to cover, the position is not extreme by squeeze-risk standards, and borrowing costs remain low at 0.28%, down sharply on the week. Availability is also ample, with roughly 68 million shares still available to borrow against 5.7 million already lent out. The lending market is loose, meaning the short book is easy to maintain or expand, but equally easy to exit without friction.

The options market is telling a different story. Put/call ratio has dropped to 0.70, almost three standard deviations below its 20-day average of 1.08. That is the most call-heavy positioning of the past year relative to the recent norm. For most of October the ratio sat above 1.15, meaning more puts than calls, so the shift since late last week is abrupt. The two signals are pulling in opposite directions: short sellers are adding shares borrowed, while options buyers are reaching for upside.

Analyst coverage reflects the same tension the market is trying to resolve. The stock spent much of 2026 in freefall, and the response from the Street after the Q2 print in August was broad-based target cuts. Jefferies, still maintaining a Buy, trimmed its target to $190 from $275 in October. Barclays initiated at Equal-Weight with a $150 target. The mean price target across the analyst community sits at $167, against a current price of $154.86, implying modest upside but limited conviction at current levels. The bull case centres on Omnipod's international momentum: OUS revenue grew 32.9% constant currency in Q2, with more than 600,000 patients on the platform and gross margin of 72.9%. The bear case is harder to dismiss. U.S. Type 2 retention deteriorated enough to force a guidance cut, the company suspended its long-range plan, and two field actions in the year dented management credibility. With Omnipod accounting for over 98% of revenue, there is no meaningful diversification cushion if the domestic slowdown deepens.

The CEO bought $162,000 of stock in the open market in August, a discretionary purchase at $147.47 per share, not a compensation grant. That is the most consequential insider transaction in the recent record, and it was made at a price below where the stock trades today. No plan was declared. BlackRock filed a fresh 13G in late October showing a 7.7% stake, the first filing from that manager in the EDGAR record for this name. No activist holder has filed a 13D.

The last two earnings prints produced sharply divergent reactions. The August 2026 Q2 release sent the stock up 5.9% the next day and 9.9% over the following week. The result before that moved the stock down 16.5% on the day and 13% over the week, one of the larger single-session drops in the company's recent history. That range alone explains why both the short book and the options market are active: the outcome is genuinely uncertain and the magnitude of the move could be large in either direction. What the Q3 report will settle, or leave unresolved, is whether U.S. Type 2 churn has stabilised and whether management's credibility on guidance has been restored after a year that has cut the share price roughly in half from its 2026 highs.